3190 results for «684»
3190 results
Challenging TAVI scenarios
14 Dec 2022 – From GulfPCR-GIM 2022
This GulfPCR-GIM 2022 session is for you if you want to learn more about recurrent valve migration during TAVR or TAVI with permanent pacemaker implantation, among others!
Challenging CTO cases - Session 2
14 Dec 2022 – From GulfPCR-GIM 2022
This GulfPCR-GIM 2022 session compiles 5 challenging CTO cases and explains how to handle them. Study for example a flush ostial RCA-CTO, PWS in a CTO feeding vessel, rotablation and intravascular lithotripsy in three-vessel disease with IVUS, or rotaburr incarceration.
The why and how of performing a successful TAVI case
14 Dec 2022 – From GulfPCR-GIM 2022
In this GulfPCR-GIM 2022 session, observe a 72-year-old male patient with NYHA class II exertional dyspnoea, CAD status after revascularisation, type II DM, CKD IIIB, recently admitted for decompensated HF and type II NSTEMI, who was referred to the clinic for aortic valve replacement.
Challenging ACS scenarios
14 Dec 2022 – From GulfPCR-GIM 2022
Topics in this GulfPCR-GIM 2022 session include the role of imaging in an unusual case of ACS in a young patient, PCI of an abnormal left coronary artery with AMI, embolisation of a thrombus in a non-culprit vessel during PCI in a late-presenting anterior STEMI, and...
PCI in stable CAD
14 Dec 2022 – From GulfPCR-GIM 2022
Study the two cases presented in this GulfPCR-GIM 2022 session to find out more about the importance of proper monitoring in detecting post-PCI complications and managing complex PCI and coronary stent loss.
Management of mitral regurgitation patients undergoing TMVI screening
13 Jan 2022
This study's results emphasise the strengths and limitations of transcatheter mitral valve implantation (TMVI) as a novel and promising therapy providing predictable elimination of MR in most patients, by S. Ludwig et al.
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)
01 Apr 2025
Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.
Author
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
30 years of primary PCI – a tale of perseverance
16 May 2023
Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.
Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.
Author
